All In Biotech

Drug Trial Radar · NCT00313911

Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.

Large Scale Safety Study of a DTaP-IPV-Hep B-PRP~T Combined Vaccine, in Comparison to Tritanrix-Hep B/Hib™ and OPV Administered at 2, 4, and 6 Months of Age in Latin American Infants

Last checked: Nov 20, 2026Latest source record: Apr 21, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,133 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,133

Actual

Start

Jul 2006

Primary completion

Jan 2008

Study completion Feb 2008

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Apr 12, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 50 days, up to 71 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To demonstrate that DTaP-IPV-HB-PRP\~T combined vaccine does not induce a higher incidence rate of high fever than Tritanrix-HepB/Hib™ and Oral Polio Vaccine (OPV) after any of the three vaccinations at 2, 4, and 6 months of age for each subject. To evaluate the overall safety in terms of: Any solicited adverse reactions in the first 7 days after each injection, Any adverse events and reactions in the first 30 days after each injection, Any serious adverse events during the trial. Immunogenicity: To document the immune response to Hepatitis B antigen of the three batches of the investigational DTaP-IPV-HB-PRP\~T vaccine.

Conditions

  • Diphtheria
  • Tetanus
  • Pertussis
  • Haemophilus Influenzae Type b
  • Hepatitis B

Interventions

  • DTaP-IPV-HB-PRP~TBiological

    0.5 mL, Intramuscular (IM)

  • Tritanrix-HepB/HibBiological

    0.5 mL, Intramuscular

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With High Fever Observed After Either DTaP-IPV-Hep B-PRP~T or Tritanrix Hep B/Hib™ + Placebo or Tritanrix-Hep B/Hib™ + Placebo Injection.Time frame: Day 0 up to Day 7 post-injection

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Mexico City, Mexico

  • Site not named

    Lima, Peru

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.